leadf
logo-loader
view4D pharma PLC
(
AIM:DDDDNASDAQ:LBPS
)

4d pharma reveals 'phenomenal results' from early stage cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton talks to Proactive London following the positive results of its clinical results in the first part of a trial on very poorly patients battling cancer.

The trial of its live biotherapeutic in combination with an established cancer drug called a checkpoint inhibitor resulted in five people, or 42% of the group, experiencing a clinically meaningful benefit from the two drugs.

Peyton explains how this is the first time live biotheroputics have been used in this way and without any side effects.

Quick facts: 4D pharma PLC

Follow
AIM:DDDD

Price: 64.105 GBX

Market Cap: £115.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE rides on wave of results and reopening optimism boosts the market mood

FTSE 100 rose as a wave of results and reopening optimism boosted the mood on investors. Anglo American and Shell were good, BT not so much and the blue-chip index was up 45 at points at 7,061. Lloyds Banking Group (LSE:LLOY) PLC declared its first interim dividend after the recent removal of...

on 29/7/21

2 min read